LGND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ligand Pharmaceuticals Inc (LGND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is supported by strong positive catalysts, bullish technical indicators, favorable analyst ratings, and a promising FDA approval that could drive long-term royalty revenue growth. Despite some recent financial challenges, the company's revenue growth and high gross margin indicate a solid foundation for future performance.
The technical indicators for LGND are bullish. The MACD is positive and contracting, RSI is neutral at 66.423, and the moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The stock is currently trading above the pivot level of 213.845, with resistance levels at 229.16 and 238.621, suggesting potential for further upside.
The FDA approval of Filspari for treating focal segmental glomerulosclerosis (FSGS) is a major positive catalyst, as it positions Ligand to benefit from long-term royalty revenue. Analysts have raised price targets following this approval, and the stock is expected to gain from its expanding portfolio in rare diseases. Additionally, the company's gross margin has improved to 81.42%, reflecting operational efficiency.
The company's net income and EPS have significantly declined YoY, with net income dropping by -244.06% and EPS by -232.32%. This could raise concerns about profitability in the short term. Additionally, there is no recent congress trading data or significant insider/hedge fund activity to provide additional confidence.
In Q4 2025, Ligand's revenue increased by 39.37% YoY to $59.67M, demonstrating strong top-line growth. However, net income dropped by -244.06% YoY to $44.78M, and EPS declined by -232.32% YoY to 2.17. Despite these declines, the gross margin improved to 81.42%, up 9.91% YoY, indicating efficient cost management.
Analysts are overwhelmingly positive on LGND, with multiple firms raising price targets and maintaining Buy ratings. Recent price target increases include Citi ($282), H.C. Wainwright ($243), and BofA ($250), reflecting confidence in the company's growth prospects following the FDA approval of Filspari and its expanding portfolio of high-value assets.
